Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risvodetinib (IkT-148009) 200mg Safety/PK in Older Adults
NCT06641557Phase 1Completed
- Sponsor
- ABLi Therapeutics, Inc.
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risvodetinib in Parkinson's disease (PD), sponsored by ABLi Therapeutics, Inc. Primary endpoints: Participant Safety, Participant Safety - vital signs and 3 more. Started Feb 2023; status: completed.
02
Drugs
risvodetinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06641557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641557.